Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. 

The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Angus Liu covered the event. 

In this week's episode of "The Top Line," they discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. 

To learn more about the topics in this episode: 
Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think?
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy

Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. 
The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Angus Liu covered the event. 
In this week's episode of "The Top Line," they discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/merck-cmo-akeso-summits-keytruda-head-head-win-maybe-another-option-issue" data-cke-saved-href="https://www.fiercepharma.com/pharma/merck-cmo-akeso-summits-keytruda-head-head-win-maybe-another-option-issue">Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think?</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-after-keytruda-merck-builds-3-prong-cancer-strategy-stars-moderna-partnered-vaccine" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-after-keytruda-merck-builds-3-prong-cancer-strategy-stars-moderna-partnered-vaccine">ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-big-pharmas-double-down-past-wins-future-success-and-steer-clear-radioligands-and-cell" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-big-pharmas-double-down-past-wins-future-success-and-steer-clear-radioligands-and-cell">ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement